Title: A Comparative Randomise Study of Chemotherapy versus Chemoradiation in Unresectable Locally Advanced Gallbladder Carcinoma
Authors: Dr Kamlesh Kumar Harsh, Dr Satya Narayan, Dr Sitaram Maharia, Dr Rajkumar Nirwan, Dr SL Jakhar, Dr Neeti Sharma, Dr HS Kumar
DOI: https://dx.doi.org/10.18535/jmscr/v5i1.132
Abstract
INTRODUCTION
Gall bladder (GB) carcinoma is most common biliary tract malignancy worldwide. (1) The incidence is increasing globally and also in India. Recently, the Indian Council of medical research (ICMR) has reported that incidence rates of GB cancer in women in Northern India (more than 9 per 100000 per year) are one of the highest in the world. Cholelithiasis is frequently associated with GB cancer in up to 40%-90% patients and is the most common associated factor independent of age or sex. (2) Surgery is potentially curative treatment in early stage of GB cancer. But vague presenting symptoms often delay the diagnosis of GB cancer, thus contributing to its overall progression and poor outcome. Overall mean survival is six months, while 5- year survival rate is only 5%. (3) Palliative therapy is the treatment which alleviates the distressing symptoms caused by advanced cancer. Palliative chemotherapy or radiotherapy helps to improve quality of life, reduces risk of complications and also has some survival benefit. In an effort to improve survival rates and quality of life, neoadjuvant or concurrent chemotherapy has been used. Radiation therapy is safe and tolerable as palliative therapy in unresectable GB cancer to relieve symptoms like abdominal pain and obstructive jaundice. It acts by shrinking tumors that are blocking passage ways for blood or bile or are pressing on nerves. (4)
The goal of the study was to evaluate the efficacy and safety of chemotherapy alone as Gemcitabine and Cisplatin versus continuous daily Capecita-bine with radiotherapy in patients with previously untreated locally advanced unresectable GB carcinoma. The primary end point was radiologic response and symptomatic evaluation. The secondary end point included overall survival and tolerability.
References
1. Zhu AX, Hong TS, Hezel AE, Kooby DA. Current management of gallbladder carcinoma .Oncologist.2010;15(2):168-81.
2. Dwivedi S, Madeshiya A, Singh D, Singh S, Krishna A. Gallbladder cancer and some epidemiological factors: A cross sectional study. Biomedical research.2013; 24(1):83-87.
3. Hundal R and Shaffer EA. Gallbladder cancer: epidemiology and outcome clinical epidemiology and outcome. Clinical epidemiology.2014;6: 99-109.
4. EngineerR , Wadasadawala T, Mehta S, Mahantshetti U, Purandare N, Rangarajan V et al. chemoradiation for unresectable gallbladder cancer: time to review historic nihilism. Journal Of Gastrointestinal Cancer.2011;42 (4):222-27.
5. Cho SY, Kim SH, Park JS , Han SS, Kim YK, Lee KW et al. Adjuvant chemoradiation therapy in gallbladder cancer. J. Surg.Oncol.2010;102:87-93.
6. Kang MH, Lee WS, Go S, Kim MJ, Lee US, Choi HJ et al. Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combina-tion chemotherapy in cholangioca-rcinoma?: Case Series. Medicine. 2014;93(28):305.
7. Kapoor R , Singh PK, Bahl A, Kumar R, Kumar N, Gupta R et al. Potential for adjuvant treatment after radical resection in carcinoma gallbladder: a tertiary care experience from india . Clin Cancer Investigation Journal.2013;2:207-11.
8. Malik IA, Aziz Z, Zaidi MSH, Sethuraman G. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. American Journal Of Clinical Oncology.2003;26 (2):174-77.
9. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs.1996; 14(3):257-63.
10. Doval DC, Sekhon JS, Gupta SK, Fuloria I, Shukla VK, Gupta S et al. A Phase II trial of gemcitabine and cisplatin in chemotherapy-naïve, unresectable gallb-ladder cancer. B J C.2004;90 : 1516-20.
11. Yamashita Y, Taketomi A, Itoh S, Harimoto N, Tsujita E, Sugimachi K et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin chemotherapy in patients with advanced biliary tree cancer .Jpn J Clin Oncol.2010; 40 (1):24-28.
12. Singh IY, Singh TT and Singh JL. Role of chemoradiation in unresectable gallbladdercarcinoma:5-years retrospective analysis of RIMS. Journal of Clinical Oncology.2008;26(155):15650.
13. Park JY , Park SW, Chung JB, Seong J, Kim KS, Lee WJ et al. concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. Amj J Cli Onc.2006;29(3):240-45.
14. Gallardo J, Rubio B, Fodon M. A phase II study of gemcitabine in gallbladder cancer. Ann Oncol.2002;12:1403-06.
15. Patt YZ , Hassan MM, Aguayo A . Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma and gallbladder carcinoma. Cancer.2004;101:578-86.
16. Knox JJ , Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer : A phase II trial.2005;23(10):2332-38.
17. Common Terminology Ceriteria for Adverse Events (CTCAT) Version 4.0 Published: may 28,2009(June V 4.03:14.2010).National Cancer Institute.